Alpha Teknova (TKNO) Company presentation summary

Business and product portfolio

• Critical supplier of reagents for therapy and diagnostic development, supporting more than 70 therapies; 3,000+ active customers, 95% retention, and ~24% of revenue from cell and gene therapy.

• Products include pre-poured agar plates, liquid microbial culture media and supplements, and molecular biology reagents for research, manufacturing, and testing.

• 2025 revenue mix: ~50% biopharma and contract manufacturing, ~30% life science tools and diagnostics, ~15% other markets, and 5% non-product revenue.

• Lab Essentials generated ~75% of 2025 revenue, with ~80% catalog and ~20% custom products; Clinical Solutions contributed ~20%, with ~90% custom products.

Clinical solutions and differentiation

• Clinical Solutions customers increased from 13 in 2020 to 60 in 2025, a 36% CAGR; customers count with at least $5,000 annual spend.

• Supported 55+ preclinical, 12 Phase 1, and 5 Phase 2/3 therapies; expected to support at least one commercial therapy or diagnostic by end-2027.

• Build Tek custom configurator enables guided product configuration in minutes; submissions are quoted in 2–3 business days, with technical review before order confirmation.

• Fill Tek single-use bag process supports 250 mL to 200 L bags, varied configurations, and GMP manufacturing; designed to improve flexibility and reduce catalog GMP manufacturing costs.

• Estimated replication barriers include $50M+ and >3 years for facilities, >5 years for modular manufacturing, and >10 years for the co-located catalog business.

Scale and growth profile

• Facilities exceed 180,000 sq. ft., including ~10,000 sq. ft. of ISO 7 cleanrooms; estimated capacity exceeds $200M in annual revenue with minimal additional capital investment.

• Lab Essentials revenue recorded an 11% CAGR from 2008–2025, providing a broad research-grade customer foundation.

• Long-term targets: sustainable 20–25% revenue growth, 60–65% gross margin, and 25–30% adjusted EBITDA margin.

• Management estimates 70% of incremental revenue growth reaches the bottom line; higher utilization, automation, and larger GMP runs are cited as operating-leverage drivers.